Misinformation about prostate cancer is widespread in online networks and commonly raised during clinical encounters. Failing to address information can result in harms for patients, and challenging discussions about misinformation can lead to discord in the patient-clinician relationship.

The management of patients with brain metastases and leptomeningeal disease (LMD) presents complex clinical challenges requiring nuanced, evidence-based decision-making.

Retroperitoneal sarcomas (RPS), a rare subset of soft tissue sarcomas, account for 10-15% of these cases and are distinguished by their substantial size, infiltrative nature, and proximity to vital anatomical structures.

Increasing evidence has demonstrated the importance of immunomodulation on tumor control. Radiotherapy, specifically, can produce a multitude of local and systemic immunomodulatory effects, including reprogramming the tumor microenvironment and exposing tumor antigens via in situ vaccination.